Form 4: Amgen EVP & CFO Peter H. Griffith Reports Stock Disposal to Cover Tax Obligations

Peter H. Griffith, EVP & CFO of Amgen, disposed of 682 shares of common stock on May 2, 2024, to satisfy tax withholding obligations related to vesting restricted stock units.

Summary

• On May 2, 2024, Peter H. Griffith, the Executive Vice President and CFO of Amgen Inc., reported a transaction involving the disposal of 682 shares of Amgen's common stock.
• The transaction was executed to cover tax obligations related to the vesting of restricted stock units (RSUs).
• Following the transaction, Griffith directly owns 33,425 shares of Amgen common stock, which includes various RSUs vesting at different dates in the future.

Sentiment

Score: 5

Explanation: This is a routine transaction related to executive compensation and tax obligations, and does not indicate any specific positive or negative sentiment about the company's performance.

Industry Context

Executive stock transactions are a routine part of corporate governance and compensation practices in the biotechnology industry. These transactions are closely watched by investors for insights into management's perspective on the company's value and future prospects.

Comparison to Industry Standards

• Executive compensation practices, including the use of RSUs and stock options, are common among large pharmaceutical companies such as Johnson & Johnson, Pfizer, and Merck.
• The vesting schedules and terms of Amgen's equity incentive plans are likely benchmarked against those of its peers to attract and retain top talent.
• Disposals of stock to cover tax obligations are a standard practice among executives receiving equity compensation.

Stakeholder Impact

• The transaction has a minimal direct impact on shareholders, as it is a routine disposal of shares by an executive to cover tax obligations.
• The transaction does not directly affect employees, customers, suppliers, or creditors.

Key Dates